Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera Safety and Efficacy in Active Rheumatoid Arthritis
NCT00503425Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2005
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 104 weeks. Started Jun 2005; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00503425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503425.